Index

VOLUME 9, 1996

Author Index

Aarsland D, 157
Adair JC, 209
Amadeo M, 142

Baker FM, 127
Bashford G, 133
Benson DF, 120
Beusterien KM, 13
Bianchetti A, 123
Binetti G, 123
Blennow K, 185
Bliwise DL, 102
Bradd P, 133

Carew TG, 146
Christine D, 1
Clark CM, 176
Clejan S, 181
Cloud BS, 146
Cohen-Mansfield J, 30
Cole MG, 100
Cremens MC, 48, 104, 155, 215
Culpepper WJ, II, 30
Cummings JL, 1
Cunningham SL, 83

Doody RS, 176
Dorsey CM, 83
Drachman DA, 22, 200

Edman Å, 185
Elie M, 100
Emmerich AD, 91
Eskin TA, 209

Ferris SH, 176
Fitten LJ, 136
Flint AJ, 164
Fratkin J, 181
Friedman EH, 102

Glick REL, 97
Gonzales JJ, 91
Gottfries C-G, 185
Gracon SI, 39
Gruber-Baldini AL, 30

Harper D, 83
Heilman KM, 209
Hødnebø A, 157
Holroyd S, 171

Ingram SM, 22
Iwamoto Y, 7

Jenike MA, 47, 57, 103, 154, 214

Kane K, 200
Karlinsky H, 26
Karlsson I, 185
Kaufer DI, 1
Kawabata K, 7
Kodama N, 7
Kunik ME, 53

Lantz MS, 107
Larsen JP, 157
Lennox A, 26
Libon DJ, 146
Lukas SE, 83

Magni E, 123
Malloy P, 146
Marin D, 107
Molinari VA, 53
Moonis M, 200
Morris JC, 176

Nishimura H, 7

Ødegaard H, 157
O'Donnell BF, 22
Okuda B, 7
Okwumabua J, 127
Olin JT, 176
Orengo CA, 53
Osgood D, 200
O'Toole C, 200
Overall JE, 39

Perryman KM, 136
Philipose V, 127
Primeau F, 100

Rauch SL, 91
Regland B, 185
Reinish L, 164
Reisberg B, 176
Rothenberg H, 146
Rye DB, 102

Index

VOLUME 9, 1996

Author Index

Aarsland D, 157
Adair JC, 209
Amadeo M, 142

Baker FM, 127
Bashford G, 133
Benson DF, 120
Beusterien KM, 13
Bianchetti A, 123
Binetti G, 123
Blennow K, 185
Bliwise DL, 102
Bradd P, 133

Carew TG, 146
Christine D, 1
Clark CM, 176
Clejan S, 181
Cloud BS, 146
Cohen-Mansfield J, 30
Cole MG, 100
Cremens MC, 48, 104, 155, 215
Culpepper WJ, II, 30
Cummings JL, 1
Cunningham SL, 83

Doody RS, 176
Dorsey CM, 83
Drachman DA, 22, 200

Edman Å, 185
Elie M, 100
Emmerich AD, 91
Eskin TA, 209

Ferris SH, 176
Fitten LJ, 136
Flint AJ, 164
Fratkin J, 181
Friedman EH, 102

Glick REL, 97
Gonzales JJ, 91
Gottfries C-G, 185
Gracon SI, 39
Gruber-Baldini AL, 30

Harper D, 83
Heilman KM, 209
Hødnebø A, 157
Holroyd S, 171

Ingram SM, 22
Iwamoto Y, 7

Jenike MA, 47, 57, 103, 154, 214

Kane K, 200
Karlinsky H, 26
Karlsson I, 185
Kaufer DI, 1
Kawabata K, 7
Kodama N, 7
Kunik ME, 53

Lantz MS, 107
Larsen JP, 157
Lennox A, 26
Libon DJ, 146
Lukas SE, 83

Magni E, 123
Malloy P, 146
Marin D, 107
Molinari VA, 53
Moonis M, 200
Morris JC, 176

Nishimura H, 7

Ødegaard H, 157
O'Donnell BF, 22
Okuda B, 7
Okwumabua J, 127
Olin JT, 176
Orengo CA, 53
Osgood D, 200
O'Toole C, 200
Overall JE, 39

Perryman KM, 136
Philipose V, 127
Primeau F, 100

Rauch SL, 91
Regland B, 185
Reinish L, 164
Reisberg B, 176
Rothenberg H, 146
Rye DB, 102

Sanders KM, 97
Satlin A, 83
Schmitt FA, 176
Schneider LS, 176
Schwartz RL, 209
Seltzer B, 181
Shapiro CM, 164
Shulman KI, 26
Sjögren M, 185
Sloan EP, 164
Srirama MK, 39
Steinwald B, 13
Stern TA, 91, 97
Sugita M, 7
Swearer JM, 22, 200

Tachibana H, 7
Takeda M, 7
Talwalker S, 39
Tandberg E, 157
Teasdale TA, 53
Teicher MH, 83
Trabucchi M, 123

Wallin A, 185
Ware JE, Jr, 13
Werner P, 30
Winkelman JW, 83
Wong S, 127
Workman RH, 53

Yachnis AT, 209
Yudofsky SC, 53

Subject Index

Activities of daily living, 32, 127–131
Adult day care, 30–37
Affective disorders, 60–61, 65
African-Americans, 127–131
Aggressivity, 142–145
Aging, 165, 166, 167
Agitation, 53–56, 107–117
Alzheimer's disease, 1–5, 7–11, 22–24, 39–46, 50, 76–77, 102, 123–125, 156, 171–174, 176–180, 215
Alzheimer's Disease Assessment Scale, 39–46
Alzheimer's Disease Cooperative Study—Clinical Global Impression of Change, 176–180
Antiandrogens, 142–145
Antidepressants, 66–68, 111–112, 116
Antipsychotics, 48, 108–111, 116
Anxiety, 72–74
Anxiolytics, 112, 116
Apolipoprotein-E, 105, 181–184
Aspiration, 133–135
Auditory evoked potentials, 7–11

Baker Belief Scale, 127–131
Balance training, 215
Balloon pump, 97–99
Behavioral problems, 68
Benzodiazepines, 69, 93–94
β-amyloid protein, 105
Beta-blockers, 68, 112–113, 116
Binswanger's disease, 7–11
Bipolar illness, 65
Blessed Dementia Scale, 200–206
Body heating, 83–89
Body temperature, 166–167
Brainstem auditory evoked potentials, 7–11
Brain syndromes, 185–191
Brief Cognitive Rating Scale, 30–37
Bupropion, 63

Carbamazepine, 68–69, 114
Cardiovascular rhythms, 168
Center for Epidemiologic Studies—Depression Scale, 127–131
Central nervous system, 63–64
Cholesterol, 53–56
Circadian rhythms, 164–169
Clinician's Global Impression of Severity and Improvement, 13–20
Clozapine, 49, 71
Cognitive Assessment Screening Test, 200–208
Cognitive function, 30–37, 39–46, 50, 53–56, 77–79
Cohen-Mansfield Agitation Inventory, 53–56
Computerized balance training, 215
Core body temperature, 166–167
Crime, 103
Cyproterone acetate, 142–145

Delirium, 74–75, 97–99, 155, 171–174, 190
Delusions, 123–125, 171–174
Dementia, 4, 49, 70, 75–76, 79, 107–117, 123–125, 142–145, 165–168, 171–174, 181–191, 200–212, 214
Depression, 13–20, 58–61, 79, 127–131, 156, 166, 167, 168, 190
Diffuse Lewy body disease, 181–184
Dopamine, 157–162
Driver's license, 49
Drugs, 57–79, 91–95, 107–117, 133–135, 157–162
Dysphagia, 133–135

Electroconvulsive therapy, 65–66, 115, 154
Epsilon 4 allele, 181–184
Event-related potentials, 7–11
Evoked potentials, 7–11
Exercise, 59–60

Falls, 215
Familial Alzheimer's disease, 22–24
Frailty, 215
Frontal syndrome, 189–190
Frontoparietal syndrome, 190
Frontosubcortical syndrome, 189

Geriatric Depression Scale, 13–20, 33, 127
Global syndrome, 190

Hallucinations, 171–174
Hamilton Depression Rating Scale, 13–20
Huntington's disease, 26–29

Idiopathic Parkinson's disease, 157–162
Insomnia, 83–89
Intra-aortic balloon pump, 97–99

Late-onset Huntington's disease, 26–29
Late-onset psychosis, 146–152
Leukoencephalopathy, 210–212
Lewy body disease, 181–184
Lithium, 63, 64, 69, 113–114
Luria, Aleksandr R., 120–122

Magnetic resonance imaging, 157–162, 209–212
Medroxyprogesterone, 142–145
Melatonin, 155, 167
Meprobamate, 91–95
Metabolism, 57
Mini-Mental State Examination, 1–5, 30–37, 53–56, 58, 172–173, 200–206
Monoamine oxidase inhibitors, 63
Mood stabilizers, 113–115, 116
Motor activity rhythm, 168
Motor vehicle operation, 136–140
Multifocal leukoencephalopathy, 210–212
Multi-infarct dementia, 123–125
Multimodal evoked potentials, 7–11

Neurofibrillary tangles, 181–184
Neuroleptic malignant syndrome, 69–70
Neuropsychiatric Inventory, 1–5
Nursing home, 48–49

Obsessive-compulsive disorder, 74

Pain, 66–68
Panic disorder, 72–74
Parietal syndrome, 190
Parkinsonism, 133–135
Parkinson's disease, 49, 102, 157–162
Passive body heating, 83–89
Post-traumatic stress disorder, 72–73
Progressive dementia, 209–212
Progressive multifocal leukoencephalopathy, 210–212
Psychiatric illnesses, 57–79
Psychosis, 59, 68, 70, 146–152
Psychotherapy, 66

Rapidly progressive dementia, 209–212
Regional brain syndromes, 185–191

Sandoz Clinical Assessment Geriatric Scale, 39
Screaming, 154
Serotonergic agents, 69
Serotonin selective reuptake inhibitors, 47, 61–63
SF-36 Health Survey, 13–20
Short Portable Mental Status Questionnaire, 127–131
Single-photon emission computed tomography, 146–152, 215
Sleep, 48–49, 83–89, 155, 165–166
Somatosensory evoked potentials, 7–11
Stepwise comparative status analysis, 185–191, 193–199
Stress disorder, 72–73
Subcortical syndrome, 189

Tacrine, 1–5
Tai Chi, 215
Thyroid hormone, 64
Tricyclics, 61
Triglyceride, 53–56

Violence, 68
Visual evoked potentials, 7–11
Visual hallucinations, 171–174

White matter lesions, 104–105